Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.
Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.
复制标题
DOI：
10.1080/1744666x.2017.1384313
复制
发表时间：
2017-11
影响因子：
4.4
通讯作者：
Sampson JH
中科院分区：
文献类型：
--
作者：
Schaller TH;Batich KA;Suryadevara CM;Desai R;Sampson JH
Immunotherapy embodies any approach that manipulates the immune system for therapeutic benefit. In this regard, various clinical trials have employed direct vaccination with patient-specific dendritic cells or adoptive T cell therapy to target highly aggressive tumors. Both modalities have demonstrated great specificity, an advantage that is unmatched by other treatment strategies. However, their full potential has yet to be realized. In this review, we provide an overview of chemokines in pathogen and anti-tumor immune responses and discuss further improving immunotherapies by arming particular chemokine axes. The chemokine macrophage inflammatory protein-1 alpha (MIP-1α, CCL3) has emerged as a potent activator of both innate and adaptive responses. Specifically, CCL3 plays a critical role in recruiting distinct immune phenotypes to intratumoral sites, is a pivotal player in regulating lymph node homing of dendritic cell subsets, and induces antigen-specific T cell responses. The recent breadth of literature outlines the various interactions of CCL3 with these cellular subsets, which have now served as a basis for immunotherapeutic translation.
